{"id":"W4388233301","doi":"10.1038/s41467-023-42744-y","title":"Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"KU Leuven; AstraZeneca","keywords":"Medicine; Clinical endpoint; Durvalumab; Triple-negative breast cancer; Carboplatin; Internal medicine; Oncology; Breast cancer; Atezolizumab; Metastatic breast cancer; Phases of clinical research; Randomized controlled trial; Clinical trial; Response Evaluation Criteria in Solid Tumors; Immunotherapy; Cancer; Chemotherapy; Nivolumab; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001185906,0.001210927,0.001518876,0.0003299831,0.0002977279,0.0007780545,0.0006024948,0.001166711,0.005450717],"category_scores_gemma":[0.0009652214,0.000500441,0.001176652,0.0002841298,0.0006332346,0.0006153047,0.0003533207,0.002222426,0.0008524184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008090539,"about_ca_system_score_gemma":0.001104233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009279339,"about_ca_topic_score_gemma":0.00252864,"domain_scores_codex":[0.9996587,0.0001740834,0.00001858687,0.00006131221,0.00003170708,0.00005556959],"domain_scores_gemma":[0.9996639,0.00008772737,0.00006734121,0.00003188019,0.00002030483,0.0001288229],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9625572,0.007102525,0.0006252121,0.0003681559,0.0006091989,0.00003876632,0.00004777119,0.0003834594,0.003755289,0.0001290281,0.0012919,0.02309149],"study_design_scores_gemma":[0.9344031,0.06181987,0.001371146,0.00002979692,0.00036316,0.000047871,0.00001884121,0.0003593855,0.0004905317,0.0001400994,0.000947524,0.000008734009],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871329,0.004018964,0.0004006338,0.001078466,0.0004261151,0.002561084,0.001207119,0.00009601401,0.003078677],"genre_scores_gemma":[0.9845908,0.002826673,0.001284075,0.001488917,0.0003550074,0.002858098,0.001840381,0.0000279188,0.004728143],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005450717,"threshold_uncertainty_score":0.01823449,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02473133456564642,"score_gpt":0.3518322965722842,"score_spread":0.3271009620066377,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}